First Manhattan’s Acadia Pharmaceuticals ACAD Stock Holding History

First Manhattan’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-375	Closed	-$6.93K	–	674
2024 Q1	$6.93K	Hold	375	–	–	﹤0.01%	1148
2023 Q4	$11.7K	Hold	375	–	–	﹤0.01%	1093
2023 Q3	$7.82K	Hold	375	–	–	﹤0.01%	1178
2023 Q2	$8.98K	Hold	375	–	–	﹤0.01%	1162
2023 Q1	$7.06K	Hold	375	–	–	﹤0.01%	1251
2022 Q4	$5.97K	Hold	375	–	–	﹤0.01%	1346
2022 Q3	$6K	Hold	375	–	–	﹤0.01%	1277
2022 Q2	$5K	Hold	375	–	–	﹤0.01%	1324
2022 Q1	$9K	Hold	375	–	–	﹤0.01%	1285
2021 Q4	$8K	Hold	375	–	–	﹤0.01%	1308
2021 Q3	$6K	Hold	375	–	–	﹤0.01%	1348
2021 Q2	$9K	Hold	375	–	–	﹤0.01%	1289
2021 Q1	$9K	Hold	375	–	–	﹤0.01%	1238
2020 Q4	$20K	Hold	375	–	–	﹤0.01%	1048
2020 Q3	$15K	Hold	375	–	–	﹤0.01%	1069
2020 Q2	$18K	Hold	375	–	–	﹤0.01%	1047
2020 Q1	$15K	Buy	375 +188	+101%	+$7.75K	﹤0.01%	1057
2019 Q4	$7K	Hold	187	–	–	﹤0.01%	1172
2019 Q3	$6K	Hold	187	–	–	﹤0.01%	1194
2019 Q2	$4K	Buy	+187	New	+$4.78K	﹤0.01%	1254

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

First Manhattan's ACAD Position: Q2 2024 in Review

First Manhattan sold out of Acadia Pharmaceuticals (ACAD) in Q2 2024, closing a stake of 375 shares — an estimated $6.93K sold.

First Manhattan first reported a position in ACAD in Q2 2019 and held it in 20 quarters. The position peaked at $20K in Q4 2020. 264 funds tracked by Wall St. Rank hold ACAD as of Q2 2024.

First Manhattan reported no remaining Acadia Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
First Manhattan sold 375 Acadia Pharmaceuticals shares in Q2 2024, an estimated $6.93K.
First Manhattan first reported a position in Acadia Pharmaceuticals in Q2 2019 and held it in 20 quarters.
First Manhattan's Acadia Pharmaceuticals position peaked at $20K in Q4 2020.
264 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.